m-Rehab OSA : Impact of a Telerehabilitation Program Associated With CPAP on Severity Markers of Obstructive Sleep Apnea Syndrome (mRehabOSA)

m-Rehab OSA : Impact of a Telerehabilitation Program Associated With CPAP on Severity Markers of Obstructive Sleep Apnea Syndrome. Prospective, Randomized, Controlled, Multicenter Study

Obstructive sleep apnea syndrome (OSA) is a common condition associated with major repercussions such as excessive daytime sleepiness and impaired quality of life as well as metabolic and cardiovascular complications. Continuous positive airway pressure (CPAP) remains the treatment of choice but its effectiveness remains limited, especially in reducing cardio-metabolic risk. Interventions to modify the lifestyle are therefore recommended in the management of OSA. The emergence of information and communication technologies is an opportunity for patients to have tools that promote self-management and behavioral changes. The recent development of telerehabilitation (TR) is a promising approach that has only been the subject of pilot studies. In a randomized, controlled and multicenter study, we propose to test the hypothesis according to which the use of a mobile TR solution, associated with continuous positive airway pressure (CPAP), will allow obese patients to adopt behavioral modifications to improve markers of severity of OSA. The analysis of big data (data-mining) will allow a better understanding of the motivational obstacles and levers.

Study Overview

• Status: Completed
• Conditions: Obstructive Sleep Apnea Syndrome
• Intervention / Treatment: Other: Telerehabilitation solution (m-Rehab)

Detailed Description

Statistical analysis plan The number of patients solicited for the study and the number of subjects included and randomized in each group will be reported on the flow chart. Premature stops (lost to follow-up, death, study withdrawals) and their reasons will be reported as well as any deviations from the protocol.

An initial descriptive analysis of each of the groups will be carried out. For qualitative variables, this description will include the number as well as the frequency of the different modalities. Concerning the quantitative variables, the description will include the number, the mean, the standard deviation, the median as well as the extreme values according to the distribution.

The comparability of the 2 groups will be verified for all the initial characteristics likely to influence the results. In the event of non-comparability on one or more parameters, an adjustment will be made on this or these parameters for the comparisons between groups of judgment criteria.

Analysis of the primary judgment criterion The variation in the evolution of the various main criteria will be compared between the 2 groups using a nonparametric means comparison test (Mann-Whitney test) or if the distribution turns out to be Gaussian and the conditions application are verified, a parametric test (Student's T).

Analysis of secondary endpoints The qualitative variables will be compared by a Chi-square test. Otherwise, if the conditions for performing this test are not met, Fisher's exact test will be used.

The quantitative variables will be compared between the two groups:

• in the case of Gaussian variables, by a student's t test or an analysis of variance
• in the case of non-Gaussian variables, by a Wilcoxon-Mann-Withney test

Longitudinal data (quality of life scores, physical activities) will be modeled by a mixed regression with the patient effect as a random variable. A linear regression model modeling the variation of the longitudinal endpoints will be fitted to the covariates having at least one trend (p <0.15) to the difference between the two arms of the study. A forward type procedure will be implemented to obtain a final multivariate model.

Management of missing data:

The IPTW method will be used. The lost to follow-up will be considered using a weighting on the inverse of the probability of being censored

• Study Type: Interventional
• Enrollment (Actual): 180
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Montpellier, France, 34080
    • CHU Montpellier

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Severe obstructive sleep apnea (apnea-hypopnea index ≥30 / hour)
• Body mass index ≥ 30 kg / m²
• age between 30 and 75 years old
• written consent

Exclusion Criteria:

• Presence of contraindications to perform exercise training (neuromuscular disease, orthopedic cause, acute coronary syndrome or stroke in the previous three months)
• Active infection, chronic inflammatory disease, cancer under treatment. Systemic treatment with immunosuppressants or corticosteroids
• Obstructive Sleep Apnea treated by Continuous Positive Airway Pressure or mandibular advancement device in the 3 months preceding inclusion
• Participation in a rehabilitation program scheduled within six months of inclusion
• Predominantly central sleep apnea syndrome (AC> 50%)
• Heart failure with Left Ventricular Ejection Fraction <40% known
• Bariatric surgery in the previous 6 months or bariatric surgery project in the 6 months
• Alcohol> 14 drinks per week
• Inability to understand and / or answer questionnaires.
• Refusal to use a smartphone or digital device
• Inability to access an internet connection at home.
• Subject in a period of relative exclusion with respect to another protocol or for which the maximum annual amount of compensation of € 4,500 has been reached.
• Subject not affiliated with a social security scheme, or not beneficiary of such a scheme.
• Pregnant or breastfeeding woman, patient unable to give her protected adult consent, vulnerable people
• Subject deprived of liberty by judicial or administrative decision

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental arm; Patients in the experimental group will be treated with CPAP (PRISMA, LOWENSTEIN®) and will have access to the m-Rehab® telerehabilitation program.	Other: Telerehabilitation solution (m-Rehab); The telerehabilitation program consists of the following elements: Mobile applications and website usable on smartphone and tablet for the patient.; Teleconsultation solution for the patient and the doctors.; Video conferencing solution for professionals involved in patient follow-up: educators in adapted physical activity, physiotherapists, psychologists, dieticians, etc.; Web interface for health professionals allowing the collection and monitoring of various parameters in physical activity and nutrition as well as progress in therapeutic education activities.; Withings® connected objects
No Intervention: Control arm; Patients in the experimental group will be treated with CPAP (PRISMA, LOWENSTEIN) and will receive the usual advice on adapted physical activity and nutrition during the initial consultation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline daytime sleepness at 6 months	Epworth questionnaire	Between baseline and 6 month visit
Change from baseline quality of life at 6 months	Functional Outcomes of Sleep Questionnaire (FOSQ)	Between baseline and 6 month visit
Change from baseline systolic blood pressure at 6 months	Blood pressure : nocturnal systolic BP (ambulatory blood pressure measurement)	Between baseline and 6 month visit
Change from baseline inflammation at 6 months	C-reactive protein in blood	Between baseline and 6 month visit

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evolution of fatigue in experimental and control group	Pichot questionnaire	Between inclusion and 6 month visit
Evolution of quality of life in experimental and control group	EQ5D (EuroQol) questionnaire	Between inclusion and 6 month visit
Evolution of sleep quality in experimental and control group	Pittsburg questionnaire	Between inclusion and 6 month visit
Evolution of anxiety and depression in experimental and control group with Hospital Anxiety and Depression scale	Anxiety and depression will be evaluated with the HAD (Hospital Anxiety and Depression) scale (values 0-21 with higher score meaning a worse outcome).	Between inclusion and 6 month visit
Evolution of sleepiness in experimental and control group (Epworth)	Percentage of patients with Epworth fall> 2	Between inclusion and 6 month visit
Evolution of sleepiness in experimental and control group (IHSS)	Assessed by the Idiopathic Hypersomnia Severity Scale. The total score is 0 to 50 with a higher score indicating more drowsiness.	Between inclusion and 6 month visit
Evolution of sleepiness in experimental and control group (iterative sleep latency tests)	Evaluated by iterative sleep latency tests	Between inclusion and 6 month visit
Evolution of the architecture of sleep in experimental and control group	Architecture of sleep will be evaluated with polysomnography : Stages of sleep (Stages N1 N2, N3 and REM in minutes and %), sleep efficiency (%), micro-arousal index (number of events/hour)	Between inclusion and 6 month visit
Evolution of polysomnographic markers in experimental and control group	time spent under a SpO2 of 90%	Between inclusion and 6 month visit
Evolution of physical activity parameters in experimental and control group (IPAQ)	evaluated by International Physical Activity Questionnaire (IPAQ)	Between inclusion and 6 month visit
Evolution of physical activity parameters in experimental and control group (actimetry)	evaluated by actimetry (number of steps)	Between inclusion and 6 month visit
Evolution of nutritional parameters in experimental and control group	assessed by dietary calendar	Between inclusion and 6 month visit
Evolution of exercise tolerance in experimental and control group	assessed by exercise test on a cycloergometer	Between inclusion and 6 month visit
Evolution of anthropometric parameters in experimental and control group	ratio of waist circumference to hip circumference	Between inclusion and 6 month visit
Evolution of biological parameters in experimental and control group (fasting blood sugar)		Between inclusion and 6 month visit
Evolution of biological parameters in experimental and control group (total cholesterol)		Between inclusion and 6 month visit
Evolution of biological parameters in experimental and control group (LDL cholesterol)		Between inclusion and 6 month visit
Evolution of biological parameters in experimental and control group (HDL cholesterol)		Between inclusion and 6 month visit
Evolution of biological parameters in experimental and control group (triglycerides)		Between inclusion and 6 month visit
Evolution of biological parameters in experimental and control group (glycated haemoglobin (HbA1c))		Between inclusion and 6 month visit
Evolution of endothelial function in experimental and control group	assessed by endoPAT	Between inclusion and 6 month visit
Evolution of blood pressure profile parameters in experimental and control group	evaluated by ambulatory blood pressure measurement over 24 hours	Between inclusion and 6 month visit
Evolution of adherence to Continuous positive airway pressure (CPAP) in experimental and control group		Between inclusion and 6 month visit
Evolution of adherence to Continuous positive airway pressure (CPAP) in experimental and control group		Between inclusion and 3 month visit
Evolution of adherence to Continuous positive airway pressure (CPAP) in experimental and control group		Between inclusion and 1 month visit
Assessment of individual factors influencing CPAP adherence in experimental and control group	The individual factors studied are gender, body mass index and age.	Between inclusion and 6 month visit
Assessment of device-related factors influencing CPAP adherence in experimental and control group	The device-related factors are are the type of mask, fixed or autopilot mode and whether or not a humidifier is used. The factors of the CPAP are: residual IAH (number/hour), the pressure P90 (cmH2O), the leaks (% and liter/minute), the duration of deep sleep (minutes and %) evaluated by the CPAP.	Between inclusion and 6 month visit
Assessment of the incremental cost-utility ratio in experimental and control group		At 6 month visit

Collaborators and Investigators

• Sponsor: University Hospital, Montpellier

Publications and helpful links

General Publications

• Bughin F, Mendelson M, Jaffuel D, Pepin JL, Gagnadoux F, Goutorbe F, Abril B, Ayoub B, Aranda A, Alagha K, Pomies P, Roubille F, Mercier J, Molinari N, Dauvilliers Y, Heraud N, Hayot M. Impact of a telerehabilitation programme combined with continuous positive airway pressure on symptoms and cardiometabolic risk factors in obstructive sleep apnea patients. Digit Health. 2023 Apr 6;9:20552076231167009. doi: 10.1177/20552076231167009. eCollection 2023 Jan-Dec.

Study record dates

Study Major Dates

• Study Start (Actual): September 27, 2021
• Primary Completion (Actual): January 5, 2024
• Study Completion (Actual): June 5, 2024

Study Registration Dates

• First Submitted: August 20, 2021
• First Submitted That Met QC Criteria: September 9, 2021
• First Posted (Actual): September 20, 2021

Study Record Updates

• Last Update Posted (Estimated): September 30, 2025
• Last Update Submitted That Met QC Criteria: September 24, 2025
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Respiratory Tract Diseases; Respiration Disorders; Sleep Wake Disorders; Apnea; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Apnea Syndromes; Sleep Apnea, Obstructive
• Other Study ID Numbers: RECHMPL19_0062; 2020-A02100-39 (Registry Identifier: ID-RCB)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No